Brief: Spruce Biosciences, HMNC To Initiate Phase 2 Study For Treatment Of MDD In Q4 2024
04/06/2024 12:53
June 4 (Reuters) - Spruce Biosciences and HMNC Brain
Health:
* SPRUCE BIOSCIENCES INC: HMNC TO INITIATE PHASE 2 STUDY FOR
TREATMENT OF MDD IN Q4 2024
Source text for Eikon: ID:nBw4lLTFKa
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium